Clinical Observation of Temozolomide and Lomustine in Treating with Gliomas

Objective To compare the therapeutic effect,survival and safety of temozolomide(TMZ) and lomustine(CCNU) on glioma. Methods A total of 64 postoperative patients with glioma were randomly divided into two groups:TMZ treatment and CCNU treatment group.All patients were performed conventional radiotherapy, 2Gy/d，5d/W，4～6 weeks as a treatment course，for a total of 50～60Gy. After radiotherapy,TMZ group were treated with TMZ (0.015～0.02)mg/(cm2·d) by orally for 5 days during 28-day cycle.CCNU group were treated with CCNU(0.005～0.006)mg/(cm2·d) by orally for 5 days during 28-day cycle. Results The effect in TMZ group were superior to CCNU group（U=1.9675，P=0.0245）；the average survival time of patients in TMZ group were longer than that of in CCNU group（t=7.7611，P=0.000）；the happening rate of nausea,vomitting and tired in TMZ group was lower than that in CCNU group（χ2=4.0635，P=0.0437）；The myelotoxicity in TMZ group were slighter than that in CCNU group（U=3.2314，P=0.0006）. Conclusion TMZ can improve the patients with gliomas in the symptoms and survival quality better,and produce higher response rate compared to CCNU in patients with gliomas.